In conclusion, our study demonstrates that CD38 deficiency improved type 2 diabetes-induced cardiomyopathy via inhibiting pyroptosis and apoptosis in vivo and in vitro, in which the underlying mechanisms were mainly related to activating Sirt3/FOXO3a signaling pathways. The gene discussed is CD38; the disease is type 2 diabetes mellitus.